Stay updated with breaking news from Yohei Doi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Japanese pharmaceutical company Shionogi has announced the first peer-reviewed publication of its phase 3 study investigating ensitrelvir to treat patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam.
Ensitrelvir (Xocova) is a new antiviral that's superior to Paxlovid — Americans can't get it, however, as it's being held up in the FDA approval process.
The antiviral drug ensitrelvir, which has not been approved outside of Japan, shortens sensory problems
The antiviral drug ensitrelvir eases both smell and taste loss, and is one of the few COVID-19 drugs available to people not at high risk of grave illness. The antiviral drug ensitrelvir eases both smell and taste loss, and is one of the few COVID-19 drugs available to people not at high risk of grave illness.
Written by Steven HansenThe U.S. new cases 7-day rolling average are 32.8 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 8.5 % LOWER than the rolling average one week ago. Today's posts include: